Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases

Progress in Retinal and Eye Research

Volumn 42, Issue , 2014, Pages 85-102

  Kandarakis, Stylianos A ^a   Piperi, Christina ^a   Topouzis, Fotis ^b   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

AGEs; Angiogenesis; Anti glycating agents; Blood retinal barrier; Eye disease; Inflammation

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADVANCED GLYCATION END PRODUCT; CELL PROTEIN; NUTRACEUTICAL; PIGMENT EPITHELIUM DERIVED FACTOR; SCLEROPROTEIN; VASCULOTROPIN;

ANGIOGENESIS; BIOCHEMISTRY; BLOOD RETINA BARRIER; BRUCH MEMBRANE; CELL ADHESION; CELL MEMBRANE PERMEABILITY; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CHRONIC DISEASE; CORNEA; CROSS LINKING; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIET; ENDOTHELIUM; ENZYME SYNTHESIS; EYE DISEASE; GENE EXPRESSION; GLAUCOMA; GLYCATION; HUMAN; IN VITRO STUDY; LENS; LIPID PEROXIDATION; NONHUMAN; OPTIC NERVE; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; QUALITY OF LIFE; RETINA; RETINA GANGLION CELL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SCLERA; SIGNAL TRANSDUCTION; VISUAL DISORDER; VITREOUS BODY; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY;

BLOOD-RETINAL BARRIER; EYE DISEASES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS;

EID: 84906058512     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2014.05.002     Document Type: Review

References (214)

1. Adamopoulos C., Farmaki E., Spilioti E., Kiaris H., Piperi C., Papavassiliou A.G. Advanced glycation end-products induce endoplasmic reticulum stress in human aortic endothelial cells. Clin. Chem. Lab. Med. 2014, 52:151-160.
2. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N.Engl. J. Med. 1994, 331:1480-1487.
3. Alizadeh M., Miyamura N., Handa J.T., Hjelmeland L.M. Human RPE cells express the FGFR2IIIc and FGFR3IIIc splice variants and FGF9 as a potential high affinity ligand. Exp. Eye Res. 2003, 76:249-256.
4. Alizadeh P., Smit-McBride Z., Oltjen S.L., Hjelmeland L.M. Regulation of cysteine cathepsin expression by oxidative stress in the retinal pigment epithelium/choroid of the mouse. Exp. Eye Res. 2006, 83:679-687.
5. Amano S., Kaji Y., Oshika T., Oka T., Machinami R., Nagai R., Horiuchi S. Advanced glycation end products in human optic nerve head. Br. J. Ophthalmol. 2001, 85:52-55.
6. Basta G., Schmidt A.M., de Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated athero sclerosis in diabetes. Cardiovasc. Res. 2004, 63:582-592.
7. Beattie J.R., Pawlak A.M., Boulton M.E., Zhang J., Monnier V.M., McGarvey J.J., Stitt A.W. Multiplex analysis of age-related protein and lipid modifications in human Bruch's membrane. FASEB J. 2010, 24:4816-4824.
8. Beattie J.R., Pawlak A.M., McGarvey J.J., Stitt A.W. Sclera as a surrogate marker for determining AGE-modifications in Bruch's membrane using a Raman spectroscopy-based index of aging. Investig. Ophthalmol. Vis. Sci. 2011, 52:1593-1598.
9. Bengmark S. Impact of nutrition on ageing and disease. Curr. Opin. Clin. Nutr. Metab. Care 2006, 9:2-7.
10. Berner A.K., Brouwers O., Pringle R., Klaassen I., Colhoun L., McVicar C., Brockbank S., Curry J.W., Miyata T., Brownlee M., Schlingemann R.O., Schalkwijk C., Stitt A.W. Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology. Diabetologia 2012, 55:845-854.
11. Bhaskar J.J., Shobha M.S., Sambaiah K., Salimath P.V. Beneficial effects of banana (Musa sp. var. elakki bale) flower and pseudostem on hyperglycemia and advanced glycation end-products (AGEs) in streptozotocin-induced diabetic rats. J.Physiol. Biochem. 2011, 67:415-425.
12. Bhatwadekar A., Glenn J.V., Figarola J.L., Scott S., Gardiner T.A., Rahbar S., Stitt A.W. Anew advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats. Br. J. Ophthalmol. 2008, 92:545-547.
13. Bierhaus A., Humpert P.M., Morcos M., Wendt T., Chavakis T., Arnold B., Stern D.M., Nawroth P.P. Understanding RAGE, the receptor for advanced glycation end products. J.Mol. Med. 2005, 83:876-886.
14. Booij J.C., Baas D.C., Beisekeeva J., Gorgels T.G., Bergen A.A. The dynamic nature of Bruch's membrane. Prog. Retin. Eye Res. 2010, 29:1-18.
15. Boulton M., Moriarty P., Jarvis-Evans J., Marcyniuk B. Regional variation and age-related changes of lysosomal enzymes in the human retinal pigment epithelium. Br. J. Ophthalmol. 1994, 78:125-129.
16. Bucala R., Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. Am. J. Kidney Dis. 1995, 26:875-888.
17. Bucciarelli L.G., Wendt T., Rong L., Lalla E., Hofmann M.A., Goova M.T., Taguchi A., Yan S.F., Yan S.D., Stern D.M., Schmidt A.M. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell. Mol. Life Sci. 2002, 59:1117-1128.
18. Cai W., He J.C., Zhu L., Chen X., Wallenstein S., Striker G.E., Vlassara H. Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet. Association with increased AGER1 expression. Am. J. Pathol. 2007, 294:145-152.
19. Cai W., He J.C., Zhu L., Chen X., Zheng F., Striker G.E., Vlassara H. Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am. J. Pathol. 2008, 173:327-336.
20. Cai W., He J.C., Zhu L., Chen X., Striker G.E., Vlassara H. AGE receptor- 1 counteracts cellular oxidant stress induced by AGEs via negative regulation of p66shc-dependent FKHRL1 phosphorylation. Am. J. Physiol. Cell Physiol. 2008, 294:C145-C152.
21. Canning P., Glenn J.V., Hsu D.K., Liu F.T., Gardiner T.A., Stitt A.W. Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Exp. Diabetes Res. 2007, 2007. 51837.
22. Castellani R.J., Harris P.L., Sayre L.M., Fujii J., Taniguchi N., Vitek M.P., Founds H., Atwood C.S., Perry G., Smith M.A. Active glycation in neu rofibrillary pathology of Alzheimer disease: Ne-(carboxymethyl) ly sine and hexitol-lysine. Free Radic. Biol. Med. 2001, 31:175-180.
23. Chen Y.D., Xu X., Xia X., Wu H., Liu K., Zheng Z., Zhu D. MMP9 is involved in glycation end-products induced increase of retinal vascular permeability in rats and the therapeutic effect of minocycline. Curr. Eye Res. 2008, 33:977-983.
24. Chiu C.J., Taylor A. Dietary hyperglycemia, glycemic index and metabolic retinal diseases. Prog. Retin. Eye Res. 2011, 30:18-53.
25. Choo-Smith L.P., Edwards H.G., Endtz H.P., Kros J.M., Heule F., Barr H., Robinson J.S., Bruining H.A., Puppels G.J. Medical applications of Raman spectroscopy: from proof of principle to clinical implementation. Biopolymers 2002, 67:1-9.
26. Cingle K.A., Kalski R.S., Bruner W.E., O'Brien C.M., Erhard P., Wyszynski R.E. Age-related changes of glycosidases in human retinal pigment epithelium. Curr. Eye Res. 1996, 15:433-438.
27. Diamanti-Kandarakis E., Piperi C., Kalofoutis A., Creatsas G. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin. Endocrinol. 2005, 62:37-43.
28. Diamanti-Kandarakis E., Piperi C., Korkolopoulou P., Kandaraki E., Levidou G., Papalois A., Patsouris E., Papavassiliou A.G. Accumulation of dietary glycotoxins in the reproductive system of normal female rats. J.Mol. Med. 2007, 85:1413-1420.
29. Diamanti-Kandarakis E., Piperi C., Patsouris E., Korkolopoulou P., Panidis D., Pawelczyk L., Papavassiliou A.G., Duleba A.J. Immunohistochemical localization of advanced glycation end-products (ages) and their receptor (rage) in polycystic and normal ovaries. Histochem. Cell Biol. 2007, 127:581-589.
30. Diamanti-Kandarakis E., Katsikis I., Piperi C., Kandaraki E., Piouka A., Papavassiliou A.G., Panidis D. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin. Endocrinol. 2008, 69:634-641.
31. Diamanti-Kandarakis E., Piperi C., Alexandraki K.I., Papailiou J., Ekonomou F., Koulouri E., Kandarakis H., Creatsas G. The acute effect of Orlistat on dietary glycotoxins in diabetics and healthy women. Minerva Endocrinol. 2009, 34:97-104.
32. Diamanti-Kandarakis E., Lambrinoudaki I., Economou F., Christou M., Piperi C., Papavassiliou A.G., Creatsas G. Androgens associated with advanced glycation end-products in postmenopausal women. Menopause 2010, 17:1182-1187.
33. de Assis A.M., Rieger D.K., Longoni A., Battu C., Raymundi S., da Rocha R.F., Andreazza A.C., Farina M., Rotta L.N., Gottfried C., Goncalves C.A., Moreira J.C., Perry M.L. High fat and highly thermolyzed fat diets promote insulin resistance and increase DNA damage in rats. Exp. Biol. Med. 2009, 234:1296-1304.
34. Dumic J., Dabelic S., Flogel M. Galectin-3: an open-ended story. Biochim. Biophys. Acta 2006, 1760:616-635.
35. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9:669-676.
36. Feskens E.J., Sluik D., van Woudenbergh G.J. Meat consumption, diabetes, and its complications. Curr. Diab. Rep. 2013, 13:298-306.
37. Fonseca V., Munshi M., Merin L.M., Bradford J.D. Diabetic retinopathy: a review for the primary care physician. South Med. J. 1996, 89:839-850.
38. Forbes J.M., Cowan S.P., Andrikopoulos S., Morley A.L., Ward L.C., Walker K.Z., Cooper M.E., Coughlan M.T. Glucose homeostasis can be differentially modulated by varying individual components of a western diet. J.Nutr. Biochem. 2013, 24:1251-1257.
39. Fosmark D.S., Torjesen P.A., Kilhovd B.K., Berg T.J., Sandvik L., Hanssen K.F., Agardh C.D., Agardh E. Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism 2006, 55:232-236.
40. Franke S., Dawczynski J., Strobel J., Niwa T., Stahl P., Stein G. Increased levels of advanced glycation end products in human cataractous lenses. J.Cataract Refract. Surg. 2003, 29:998-1004.
41. Gardiner T.A., Anderson H.R., Stitt A.W. Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes. J.Pathol. 2003, 201:328-333.
42. Garg T.K., Chang J.Y. 15-deoxy-delta 12, 14-Prostaglandin J2 prevents reactive oxygen species generation and mitochondrial membrane depolarization induced by oxidative stress. BMC Pharmacol. 2004, 4:6.
43. Glenn J.V., Beattie J.R., Barrett L., Frizzell N., Thorpe S.R., Boulton M.E., McGarvey J.J., Stitt A.W. Confocal Raman microscopy can quantify advanced glycation end product (AGE) modifications in Bruch's membrane leading to accurate, nondestructive prediction of ocular aging. FASEB J. 2007, 21:3542-3552.
44. Glenn J.V., Stitt A.W. The role of advanced glycation end products in retinal ageing and disease. Biochim. Biophys. Acta 2009, 1790:1109-1116.
45. Glenn J.V., Mahaffy H., Wu K., Smith G., Nagai R., Simpson D.A., Boulton M.E., Stitt A.W. Advanced glycation end product (AGE) accumulation on Bruch's membrane: links to age-related RPE dysfunction. Investig. Ophthalmol. Vis. Sci. 2009, 50:441-451.
46. Glenn J.V., Mahaffy H., Dasari S., Oliver M., Chen M., Boulton M.E., Xu H., Curry W.J., Stitt A.W. Proteomic profiling of human retinal pigment epithelium exposed to an advanced glycation-modified substrate. Graefes Arch. Clin. Exp. Ophthalmol. 2011, 250:349-359.
47. Goldin A., Beckman J.A., Schmidt A.M., Creager M.A. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006, 114:597-605.
48. Goldberg T., Cai W., Peppa M., Dardaine V., Baliga B.S., Uribarri J., Vlassara H. Advanced glycoxidation end products in commonly consumed foods. J.Am. Diet. Assoc. 2004, 104:1287-1291.
49. Gul A., Rahman M.A., Salim A., Simjee S.U. Advanced glycation end products in senile diabetic and nondiabetic patients with cataract. J.Diabetes Complicat. 2009, 23:343-348.
50. Haitoglou C.S., Tsilibary E.C., Brownlee M., Charonis A.S. Altered cellular interactions between endothelial cells and nonenzymatically glycosylated laminin/type IV collagen. J.Biol. Chem. 1992, 267:12404-12407.
51. Hammes H.P., Strödter D., Weiss A., Bretzel R.G., Federlin K., Brownlee M. Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model. Diabetologia 1995, 38:656-660.
52. Hammes H.P., Alt A., Niwa T., Clausen J.T., Bretzel R.G., Brownlee M., Schleicher E.D. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 1999, 42:728-736.
53. Handa J.T., Verzijl N., Matsunaga H., Aotaki-Keen A., Lutty G.A., te Koppele J.M., Miyata T., Hjelmeland L.M. Increase in the advanced glycation end product pentosidine in Bruch's membrane with age. Investig. Ophthalmol. Vis. Sci. 1999, 40:775-779.
54. Hashimoto H., Arai K., Chikuda M., Obara Y. Relationship between vascular endothelial growth factors and advanced glycation end products in the human vitreous. Nihon Ganka Gakkai Zasshi. 1998, 102:442-446.
55. Haus J.M., Carrithers J.A., Trappe S.W., Trappe T.A. Collagen, cross-linking and advanced glycation end-products in aging human skeletal muscle. J.Appl. Physiol. 2007, 103:2068-2076.
56. Heidland A., Sebekova K., Schinzel R. Advanced glycation end products and the progressive course of renal disease. Am. J. Kidney Dis. 2001, 38:S100-S106.
57. Hein G.E. Glycation end products in osteoporosis-is there a pathophysiologic importance?. Clin. Chim. Acta 2006, 371:32-36.
58. Hirata C., Nakano K., Nakamura N., Kitagawa Y., Shigeta H., Hasegawa G., Ogata M., Ikeda T., Sawa H., Nakamura K., Ienaga K., Obayashi H., Kondo M. Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells. Biochem. Biophys. Res. Commun. 1997, 236:712-715.
59. Hjelmeland L.M., Cristofolo V.J., Funk W., Rakoczy E., Katz M.L. Senescence of the retinal pigment epithelium. Mol. Vis. 1999, 5:33.
60. Hoffmann S., Friedrichs U., Eichler W., Rosenthal A., Wiedemann P. Advanced glycation end products induce choroidal endothelial cell proliferation, matrix metalloproteinase-2 and VEGF upregulation invitro. Graefes Arch. Clin. Exp. Ophthalmol. 2002, 240:996-1002.
61. Hong S.B., Lee K.W., Handa J.T., Joo C.K. Effect of advanced glycation end products on lens epithelial cells invitro. Biochem. Biophys. Res. Commun. 2000, 275:53-59.
62. Horwitz J., Bova M.P., Ding L.L., Haley D.A., Stewart P.L. Lens alpha-crystallin: function and structure. Eye 1999, 13:403-408.
63. Howes K.A., Liu Y., Dunaief J.L., Milam A., Frederick J.M., Marks A., Baehr W. Receptor for advanced glycation end products and age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 2004, 45:3713-3720.
64. Huang L., Yu W., Li X., Xu Y., Niu L., He X., Dong J., Yan Z. Expression of Robo4 in the fibrovascular membranes from patients with proliferative diabetic retinopathy and its role in RF/6A and RPE cells. Mol. Vis. 2009, 15:1057-1069.
65. Hyogo H., Yamagishi S. Advance glycation end products (AGEs) and their involvement in liver disease. Curr. Pharm. Des. 2008, 14:969-972.
66. Ikeda T. The pathogenesis of vitreoretinal diseases from the standpoint of molecular biology. Nihon Ganka Gakkai Zasshi. 2003, 107:785-812.
67. Inagaki Y., Yamagishi S., Okamoto T., Takeuchi M., Amano S. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia 2003, 46:284-287.
68. Inagi R. Inhibitors of advanced glycation and endoplasmic reticulum stress. Methods Enzymol. 2011, 491:361-380.
69. Ishibashi T., Murata T., Hangai M., Nagai R., Horiuchi S., Lopez P.F., Hinton D.R., Ryan S.J. Advanced glycation end products in age-related macular degeneration. Arch. Ophthalmol. 1998, 116:1629-1632.
70. Ishibashi T. Cell biology of intraocular vascular diseases. Nihon Ganka Gakkai Zasshi. 1999, 103:923-947.
71. Jin S., Cho K.H. Water extracts of cinnamon and clove exhibits potent inhibition of protein glycation and anti-atherosclerotic activity invitro and invivo hypolipidemic activity in zebrafish. Food Chem. Toxicol. 2011, 49:1521-1529.
72. Joussen A.M., Poulaki V., Mitsiades N., Kirchhof B., Koizumi K., Döhmen S., Adamis A.P. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 2002, 16:438-440.
73. Joussen A.M., Poulaki V., Qin W., Kirchhof B., Mitsiades N., Wiegand S.J., Rudge J., Yancopoulos G.D., Adamis A.P. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion invivo. Am. J. Pathol. 2002, 160:501-509.
74. Kaji Y., Usui T., Oshika T., Matsubara M., Yamashita H., Araie M., Murata T., Ishibashi T., Nagai R., Horiuchi S., Amano S. Advanced glycation endproducts in diabetic corneas. Investig. Ophthalmol. Vis. Sci. 2000, 41:362-368.
75. Kaji Y., Amano S., Usui T., Suzuki K., Tanaka S., Oshika T., Nagai R., Horiuchi S. Advanced glycation end products in Descemet's membrane and their effect on corneal endothelial cell. Curr. Eye Res. 2001, 23:469-477.
76. Kaji Y., Amano S., Usui T., Oshika T., Yamashiro K., Ishida S., Suzuki K., Tanaka S., Adamis A.P., Nagai R., Horiuchi S. Expression and function of receptors for advanced glycation end products in bovine corneal endothelial cells. Investig. Ophthalmol. Vis. Sci. 2003, 44:521-528.
77. Kaji Y., Usui T., Ishida S., Yamashiro K., Moore T.C., Moore J., Yamamoto Y., Yamamoto H., Adamis A.P. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Investig. Ophthalmol. Vis. Sci. 2007, 48:858-865.
78. Kanková K. Diabetic threesome (hyperglycaemia, renal function and nutrition) and advanced glycation end products: evidence for the multiple-hit agent?. Proc. Nutr. Soc. 2008, 67:60-74.
79. Karachalias N., Babaei-Jadidi R., Ahmed N., Thornalley P.J. Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem. Soc. Trans. 2003, 31:1423-1425.
80. Kase S., Ishida S., Rao N.A. Increased expression of αA-crystallin in human diabetic eye. Int. J. Mol. Med. 2011, 28:505-511.
81. Kass D.A., Shapiro E.P., Kawaguchi M., Capriotti A.R., Scuteri A., de Groof R.C., Lakatta E.G. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001, 104:1464-1470.
82. Kim J., Kim C.S., Sohn E., Kim H., Jeong I.H., Kim J.S. Lens epithelial cell apoptosis initiates diabetic cataractogenesis in the Zucker diabetic fatty rat. Graefes Arch. Clin. Exp. Ophthalmol. 2010, 248:811-818.
83. Kim J., Kim C.S., Sohn E., Jeong I.H., Kim H., Kim J.S. Involvement of advanced glycation end products, oxidative stress and nuclear factor-kappaB in the development of diabetic keratopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2011, 249:529-536.
84. Kim J., Kim O.S., Kim C.S., Sohn E., Jo K., Kim J.S. Accumulation of argpyrimidine, a methylglyoxal-derived advanced glycation end product, increases apoptosis of lens epithelial cells both invitro and invivo. Exp. Mol. Med. 2012, 44:167-175.
85. Kowluru R.A. Effect of advanced glycation end products on accelerated apoptosis of retinal capillary cells under invitro conditions. Life Sci. 2005, 76:1051-1060.
86. Krafft C., Sergo V. Biomedical applications of Raman and infrared spectroscopy to diagnose tissues. Spectroscopy 2006, 20:195-218.
87. Kumar P.A., Kumar M.S., Reddy G.B. Effect of glycation on alpha-crystallin structure and chaperone-like function. Biochem. J. 2007, 408:251-258.
88. Lee H.J., Howell S.K., Sanford R.J., Beisswenger P.J. Methylglyoxal can modify GAPDH activity and structure. Ann. N. Y. Acad. Sci. 2005, 1043:135-145.
89. Lee J.J., Hsiao C.C., Yang I.H., Chou M.H., Wu C.L., Wei Y.C., Chen C.H., Chuang J.H. High-mobility group box 1 protein is implicated in advanced glycation end products-induced vascular endothelial growth factor A production in the rat retinal ganglion cell line RGC-5. Mol. Vis. 2012, 18:838-850.
90. Levi B., Werman M.J. Long-term fructose consumption accelerates glycation and several age-related variables in male rats. J.Nutr. 1998, 128:1442-1449.
91. Li J.J., Dickson D., Hof P.R., Vlassara H. Receptors for advanced glycosylation endproducts in human brain: role in brain homeostasis. Mol. Med. 1998, 4:46-60.
92. Li L., Renier G. Activation of nicotinamide adenine dinucleotide phosphate (reduced form) oxidase by advanced glycation end products links oxidative stress to altered retinal vascular endothelial growth factor expression. Metabolism 2006, 55:1516-1523.
93. Liu F.T., Patterson R.J., Wang J.L. Intracellular functions of galectins. Biochim. Biophys. Acta 2002, 1572:263-273.
94. Lu M., Kuroki M., Amano S., Tolentino M., Keough K., Kim I., Bucala R., Adamis A.P. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J.Clin. Investig. 1998, 101:1219-1224.
95. Luevano-Contreras C., Garay-Sevilla M.E., Preciado-Puga M., Chapman-Novakofsk,i K.M. The relationship between dietary advanced glycation end products and indicators of diabetes severity in Mexicans and non-Hispanic whites: a pilot study. Int. J. Food Sci. Nutr. 2013, 64:16-20.
96. Mamputu J.C., Renier G. Signalling pathways involved in retinal endothelial cell proliferation induced by advanced glycation end products: inhibitory effect of gliclazide. Diabetes Obes. Metab. 2004, 6:95-103.
97. Marinakis E., Bagkos G., Piperi C., Roussou P., Diamanti-Kandarakis E. Critical role of RAGE in lung physiology and tumorigenesis: a potential target of therapeutic intervention?. Clin. Chem. Lab. Med. 2014, 52:189-200.
98. McDermott A.M., Xiao T.L., Kern T.S., Murphy C.J. Non-enzymatic glycation in corneas from normal and diabetic donors and its effects on epithelial cell attachment invitro. Optometry 2003, 74:443-452.
99. McKenna D.J., Nelson J., Stitt A.W. Advanced glycation alters expression of the 67kDa laminin receptor in retinal microvascular endothelial cells. Life Sci. 2001, 68:2695-2703.
100. Mesias M., Navarro M., Gökmen V., Morales F.J. Antiglycative effect of fruit and vegetable seed extracts: inhibition of AGE formation and carbonyl-trapping abilities. J.Sci. Food Agric. 2013, 93:2037-2044.
101. Milne R., Brownstein S. Advanced Glyction end products in diabetic retinopathy. Amino Acids 2013, 44:1397-1407.
102. Monnier V.M., Sell D.R., Nagaraj R.H., Miyata S., Grandhee S., Odetti P., Ibrahim S.A. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes 1992, 41:36-41.
103. Moore T.C., Moore J.E., Kaji Y., Frizzell N., Usui T., Poulaki V., Campbell I.L., Stitt A.W., Gardiner T.A., Archer D.B., Adamis A.P. The role of advanced glycation end products in retinal microvascular leukostasis. Investig. Ophthalmol. Vis. Sci. 2003, 44:4457-4464.
104. Morcos M., Du X., Pfisterer F., Hutter H., Sayed A.A., Thornalley P., Ahmed N., Baynes J., Thorpe S., Kukudov G., Schlotterer A., Bozorgmehr F., El Baki R.A., Stern D., Moehrlen F., Ibrahim Y., Oikonomou D., Hamann A., Becker C., Zeier M., Schwenger V., Miftari N., Humpert P., Hammes H.P., Buechler M., Bierhaus A., Brownlee M., Nawroth P.P. Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans. Aging Cell 2008, 7:260-269.
105. Mukhopadhyay S., Mukherjee T.K. Bridging advanced glycation end product, receptor for advanced glycation end product and nitric oxide with hormonal replacement/estrogen therapy in healthy versus diabetic postmenopausal women: a perspective. Biochim. Biophys. Acta 2005, 1745:145-155.
106. Murata T., Nagai R., Ishibashi T., Inomuta H., Ikeda K., Horiuchi S. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia 1997, 40:764-769.
107. Muthenna P., Akileshwari C., Reddy G.B. Ellagic acid, a new antiglycating agent: its inhibition of N-(carboxymethyl)lysine. Biochem. J. 2012, 442:221-230.
108. Muthenna P., Akileshwari C., Saraswat M., Bhanuprakash Reddy G. Inhibition of advanced glycation end-product formation on eye lens protein by rutin. Br. J. Nutr. 2012, 107:941-949.
109. Nagaraj R.H., Sarkar P., Mally A., Biemel K.M., Lederer M.O., Padayatti P.S. Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal. Arch. Biochem. Biophys. 2002, 402:110-119.
110. Nagaraj R.H., Linetsky M., Stitt A.W. The pathogenic role of Maillard reaction in the aging eye. Amino Acids 2012, 42:1205-1220.
111. Neeper M., Schmidt A.M., Brett J., Yan S.D., Wang F., Pan Y.C., Elliston K., Stern D., Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J.Biol. Chem. 1992, 267:14998-15004.
112. Ni J., Yuan X., Gu J., Yue X., Gu X., Nagaraj R.H., Crabb J.W. Clinical Genomic and Proteomic AMD Study Group. Plasma protein pentosidine and carboxym ethyllysine, biomarkers for age-related macular degeneration. Mol. Cell. Proteomics 2009, 8:1921-1933.
113. Obata H., Kaburaki T., Kato M., Yamashita H. Expression of TGF-beta type I and type II receptors in rat eyes. Curr. Eye Res. 1996, 15:335-340.
114. Onyango I.G., Tuttle J.B., Bennett J.P. Altered intracellular signaling and reduced viability of Alzheimer's disease neuronal cybrids is reproduced by beta-amyloid peptide acting through receptor for advanced glycation end products (RAGE). Mol. Cell. Neurosci. 2005, 29:333-343.
115. Padayatti P.S., Jiang C., Glomb M.A., Uchida K., Nagaraj R.H. High concentrations of glucose induce synthesis of argpyrimidine in retinal endothelial cells. Curr. Eye Res. 2001, 23:106-115.
116. Padival S., Nagaraj R.H. Pyridoxamine inhibits maillard reactions in diabetic rat lenses. Ophthalmic. Res. 2006, 38:294-302.
117. Papachroni K.K., Piperi C., Levidou G., Korkolopoulou P., Pawelczyk L., Diamanti-Kandarakis E., Papavassiliou A.G. Lysyl oxidase interacts with AGE signalling to modulate collagen synthesis in polycystic ovarian tissue. J.Cell. Mol. Med. 2010, 14:2460-2469.
118. Park H., Adsit F.G., Boyington J.C. The 1.5 A crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding. J.Biol. Chem. 2010, 285:40762-40770.
119. Pashikanti S., de Alba D.R., Boissonneault G.A., Cervantes-Laurean D. Rutin metabolites: novel inhibitors of nonoxidative advanced glycation end products. Free Radic. Biol. Med. 2010, 48:656-663.
120. Patel K., Gadewar M., Tahilyani V., Patel D.K. Areview on pharmacological and analytical aspects of diosmetin: a concise report. Chin. J. Integr. Med. 2013, 19:792-800.
121. Pawlak A.M., Glenn J.V., Beattie J.R., McGarvey J.J., Stitt A.W. Advanced glycation as a basis for understanding retinal aging and noninvasive risk prediction. Ann. N. Y. Acad. Sci. 2008, 1126:59-65.
122. Pawlak A.M., Beattie J., Glenn J., Stitt A., McGarvey J. Raman spectroscopy of advanced glycation end products (AGEs), possible markers for progressive retinal dysfunction. J.Raman Spec. 2008, 39:1635-1642.
123. Pozzi A., Zent R., Chetyrkin S., Borza C., Bulus N., Chuang P., Chen D., Hudson B., Voziyan P. Modification of collagen IV by glucose or methylglyoxal alters distinct mesangial cell functions. J.Am. Soc. Nephrol. 2009, 20:2119-2125.
124. Puddu A., Sanguineti R., Durante A., Nicolò M., Viviani G.L. Vascular endothelial growth factor-C secretion is increased by advanced glycation end-products: possible implication in ocular neovascularization. Mol. Vis. 2012, 18:2509-2517.
125. Pugliese G., Pricci F., Leto G., Amadio L., Iacobini C., Romeo G., Lenti L., Sale P., Gradini R., Liu F.-T., Di Mario U. The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression. Diabetes 2000, 49:1249-1257.
126. Pugliese G., Pricci F., Iacobini C., Leto G., Amadio L., Barsotti P., Frigeri L., Hsu D.K., Vlassara H., Liu F.T., Di Mario U. Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J. 2001, 15:2471-2479.
127. Qaum T., Pricci F., Leto G., Amadio L., Iacobini C., Romeo G., Lenti L., Sale P., Gradini R., Liu F.T., Di Mario U. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Investig. Ophthalmol. Vis. Sci. 2001, 42:2408-2413.
128. Queisser M.A., Yao D., Geisler S., Hammes H.P., Lochnit G., Schleicher E.D., Brownlee M., Preissner K.T. Hyperglycemia impairs proteasome function by methylglyoxal. Diabetes 2010, 59:670-678.
129. Ramasamy R., Vannucci S.J., Yan S.S., Herold K., Yan S.F., Schmidt A.M. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005, 15:16R-28R.
130. Renganathan K., Gu J., Rayborn M.E., Crabb J.S., Salomon R.G., Collier R.J., Kapin M.A., Romano C., Hollyfield J.G., Crabb J.W. CEP biomarkers as potential tools for monitoring therapeutics. PLoS One 2013, 8:e76325.
131. Rodriguez J., Sanchez R., Munoz B., West S.K., Broman A., Snyder R.W., Klein R., Quigley H. Causes of blindness and visual impairment in a population-based sample of U.S. Hispanics. Ophthalmology 2002, 109:737-743.
132. Rollin R., Mediero A., Roldán-Pallarés M., Fernández-Cruz A., Fernández-Durango R. Natriuretic peptide system in the human retina. Mol. Vis. 2004, 10:15-22.
133. Rosca M.G., Mustata T.G., Kinter M.T., Ozdemir A.M., Kern T.S., Szweda L.I., Brownlee M., Monnier V.M., Weiss M.F. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am. J. Physiol. Ren. Physiol. 2005, 289:F420-F430.
134. Riuzzi F., Sorci G., Donato R. The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation invivo. J.Biol. Chem. 2006, 281:8242-8253.
135. Saraswat M., Suryanarayana P., Reddy P.Y., Patil M.A., Balakrishna N., Reddy G.B. Antiglycating potential of Zingiber officinalis and delay of diabetic cataract in rats. Mol. Vis. 2010, 16:1525-1537.
136. Satish Kumar M., Mrudula T., Mitra N., Bhanuprakash Reddy G. Enhanced degradation and decreased stability of eye lens alpha-crystallin upon methylglyoxal modification. Exp. Eye Res. 2004, 79:577-583.
137. Sato E., Mori F., Igarashi S., Abiko T., Takeda M., Ishiko S., Yoshida A. Corneal advanced glycation end products increase in patients with proliferative diabetic retinopathy. Diabetes Care 2001, 24:479-482.
138. Schalkwijk C.G., Miyata T. Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics. Amino Acids 2012, 42:1193-1204.
139. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M. The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta 2000, 1498:99-111.
140. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J.Clin. Investig. 2001, 108:949-955.
141. Schuster V.L., Lu R., Coca-Prados M. The prostaglandin transporter is widely expressed in ocular tissues. Surv. Ophthalmol. 1997, 41:S41-S45.
142. Schutt F., Bergmann M., Holz F.G., Kopitz J. Proteins modified by malondialdehyde, 4-hydroxynonenal, or advanced glycation end products in lipofuscin of human retinal pigment epithelium. Investig. Ophthalmol. Vis. Sci. 2003, 44:3663-3668.
143. Scivittaro V., Ganz M.B., Weiss M.F. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am. J. Physiol. Ren. Physiol. 2000, 278:F676-F683.
144. Sebag J., Buckingham B., Charles M.A., Reiser K. Biochemical abnormalities in vitreous of humans with proliferative diabetic retinopathy. Arch. Ophthalmol. 1992, 110:1472-1476.
145. Semba R.D., Nicklett E.J., Ferrucci L. Does accumulation of advanced glycation end products contribute to the aging phenotype?. J.Gerontol. A. Biol. Sci. Med. Sci. 2010, 65:963-975.
146. Semba R.D., Cotch M.F., Gudnason V., Eiríksdottir G., Harris T.B., Sun K., Klein R., Jonasson F., Ferrucci L., Schaumberg D.A. Serum carboxymethyllysine, an advanced glycation end product, and age-related macular degeneration: the age, gene/environment susceptibility-reykjavik study. JAMA Ophthalmol. 2014, 132:464-470.
147. Semenza G.L. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr. Opin. Genet. Dev. 1998, 8:588-594.
148. Semenza G.L. Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem. Pharmacol. 2000, 59:47-53.
149. Sensi M., Pricci F., Pugliese G., De Rossi M.G., Petrucci A.F., Cristina A., Morano S., Pozzessere G., Valle E., Andreani D. Role of advanced glycation end-products (AGE) in late diabetic complications. Diabetes Res. Clin. Pract. 1995, 28:9-17.
150. Shamsi F.A., Boulton M. Inhibition of RPE lysosomal and antioxidant activity by the age pigment lipofuscin. Investig. Ophthalmol. Vis. Sci. 2001, 42:3041-3046.
151. Sheikpranbabu S., Haribalaganesh R., Gurunathan S. Pigment epithelium-derived factor inhibits advanced glycation end-products-induced cytotoxicity in retinal pericytes. Diabetes Metab. 2011, 37:505-511.
152. Shobana S., Harsha M.R., Platel K., Srinivasan K., Malleshi N.G. Amelioration of hyperglycaemia and its associated complications by finger millet (Eleusine coracana L.) seed coat matter in streptozotocin-induced diabetic rats. Br. J. Nutr. 2012, 104:1787-1795.
153. Singh R., Barden A., Mori T., Beilin L. Advanced glycation end-products: a review. Diabetologia 2001, 44:129-146.
154. Singh S., Zheng J.J., Peiper S.C., Mclaughlin B.J. Gene expression profile of ARPE-19 during repair of the monolayer. Graefes Arch. Clin. Exp. Ophthalmol. 2001, 239:946-951.
155. Smedsrod B., Melkko J., Araki N., Sano H., Horiuchi S. Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells. Biochem. J. 1997, 322:567-573.
156. Snow L.M., Fugere N.A., Thompson L.V. Advanced glycation end-product accumulation and associated protein modification in type II skeletal muscle with aging. J.Gerontol. A. Biol. Sci. Med. Sci. 2007, 62:1204-1210.
157. Soro-Paavonen A., Zhang W.Z., Venardos K., Coughlan M.T., Harris E., Tong D.C., Brasacchio D., Paavonen K., Chin-Dusting J., Cooper M.E., Kaye D., Thomas M.C., Forbes J.M. Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase. J.Hypertens. 2010, 28:780-788.
158. Sparvero L.J., Asafu-Adjei D., Kang R., Tang D., Amin N., Im J., Rutledge R., Lin B., Amoscato A.A., Zeh H.J., Lotze M.T. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J.Transl. Med. 2009, 7:17.
159. Stern D., Yan S.D., Yan S.F., Schmidt A.M. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv. Drug Deliv. Rev. 2002, 54:1615-1625.
160. Stevens A. The effectiveness of putative anti-cataract agents in the prevention of protein glycation. J.Am. Optom. Assoc. 1995, 66:744-749.
161. Stitt A.W., Li Y.M., Gardiner T.A., Bucala R., Archer D.B., Vlassara H. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am. J. Pathol. 1997, 150:523-531.
162. Stitt A.W., Moore J.E., Sharkey J.A., Murphy G., Simpson D.A., Bucala R., Vlassara H., Archer D.B. Advanced glycation end products in vitreous: structural and functional implications for diabetic vitreopathy. Investig. Ophthalmol. Vis. Sci. 1998, 39:2517-2523.
163. Stitt A.W., Bhaduri T., McMullen C.B., Gardiner T.A., Archer D.B. Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. Mol. Cell Biol. Res. Commun. 2000, 3:380-388.
164. Stitt A.W., Burke G.A., Chen F., McMullen C.B., Vlassara H. Advanced glycation end-product receptor interactions on microvascular cells occur within caveolin-rich membrane domains. FASEB J. 2000, 14:2390-2392.
165. Stitt A.W. Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br. J. Ophthalmol. 2001, 85:746-753.
166. Stitt A., Gardiner T.A., Alderson N.L., Canning P., Frizzell N., Duffy N., Boyle C., Januszewski A.S., Chachich M., Baynes J.W., Thorpe S.R. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002, 51:2826-2832.
167. Stitt A.W. The maillard reaction in eye diseases. Ann. N. Y. Acad. Sci. 2005, 1043:582-597.
168. Sugiyama T., Okuno T., Fukuhara M., Oku H., Ikeda T., Obayashi H., Ohta M., Fukui M., Hasegawa G., Nakamura N. Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes. Exp. Eye Res. 2007, 85:406-412.
169. Swamy-Mruthinti S., Shaw S.M., Zhao H.R., Green K., Abraham E.C. Evidence of a glycemic threshold for the development of cataracts in diabetic rats. Curr. Eye Res. 1999, 18:423-429.
170. Tanaka N., Yonekura H., Yamagishi S., Fujimori H., Yamamoto Y., Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa b, and by 17beta-estradiol through sp-1 in human vascular endothelial cells. J.Biol. Chem. 2000, 275:25781-25790.
171. Tezel G., Luo C., Yang X. Accelerated aging in glaucoma: immunohistochemical assessment of advanced glycation end products in the human retina and optic nerve head. Investig. Ophthalmol. Vis. Sci. 2007, 48:1201-1211.
172. Thornalley P.J., Langborg A., Minhas H.S. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J. 1999, 344:109-116.
173. Thorpe S.R., Baynes J.W. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 2003, 25:275-281.
174. Throckmorton D.C., Brogden A.P., Min B., Rasmussen H., Kashgarian M. PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int. 1995, 48:111-117.
175. Touré F., Zahm J.M., Garnotel R., Lambert E., Bonnet N., Schmidt A.M., Vitry F., Chanard J., Gillery P., Rieu P. Receptor for advanced glycation end-products (RAGE) modulates neutrophil adhesion and migration on glycoxidated extracellular matrix. Biochem. J. 2008, 416:255-261.
176. Treins C., Giorgetti-Peraldi S., Murdaca J., Van Obberghen E. Regulation of vascular endothelial growth factor expression by advanced glycation end products. J.Biol. Chem. 2001, 276:43836-43841.
177. Unakar N.J., Johnson M., Tsui J., Cherian M., Abraham E.C. Effect of germanium-132 on galactose cataracts and glycation in rats. Exp. Eye Res. 1995, 61:155-164.
178. Vlassara H., Fuh H., Makita Z., Krungkrai S., Cerami A., Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:12043-12047.
179. Vlassara H., Bucala R. Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Diabetes 1996, 45:S65-S66.
180. Vlassara H., Cai W., Crandall J., Goldberg T., Oberstein R., Dardaine V., Peppa M., Rayfield E.J. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:15596-15601.
181. Verzijl N., DeGroot J., Thorpe S.R., Bank R.A., Shaw J.N., Lyons T.J., Bijlsma J.W., Lafeber F.P., Baynes J.W., TeKoppele J.M. Effect of collagen turnover on the accumulation of advanced glycation end products. J.Biol. Chem. 2000, 275:39027-39031.
182. Vlassara H., Striker G. Glycotoxins in the diet promote diabetes and diabetic complications. Curr. Diab. Rep. 2007, 7:235-241.
183. Vlassara H., Palace M.R. Glycoxidation: the menace of diabetes and aging. Mt. Sinai J. Med. 2003, 70:232-241.
184. Wang Z., Paik D.C., Del Priore L.V., Burch R.L., Gaillard E.R. Nitrite-modified extracellular matrix proteins deleteriously affect retinal pigment epithelial cell function and viability: a comparison study with nonenzymatic glycation mechanisms. Curr. Eye Res. 2005, 30:691-702.
185. Wang A.L., Yu A.C., He Q.H., Zhu X., Tso M.O. AGEs mediated expression and secretion of TNF alpha in rat retinal microglia. Exp. Eye Res. 2007, 84:905-913.
186. Wang M.Y., Ross-Cisneros F.N., Aggarwal D., Liang C.Y., Sadun A.A. Receptor for advanced glycation end products is upregulated in optic neuropathy of Alzheimer's disease. Acta Neuropathol. 2009, 118:381-389.
187. Warboys C.M., Toh H.B., Fraser P.A. Role of NADPH oxidase in retinal microvascular permeability increase by RAGE activation. Investig. Ophthalmol. Vis. Sci. 2009, 50:1319-1328.
188. Warboys C.M., Fraser P.A. Hyperglycemia attenuates acute permeability response to advanced glycation end products in retinal microvasculature. Microvasc. Res. 2010, 80:174-176.
189. Weikel K.A., Fitzgerald P., Shang F., Caceres M.A., Bian Q., Handa J.T., Stitt A.W., Taylor A. Natural history of age-related retinal lesions that precede AMD in mice fed high or low glycemic index diets. Investig. Ophthalmol. Vis. Sci. 2012, 53:622-632.
190. Wolffenbuttel B.H., Boulanger C.M., Crijns F.R., Huijberts M.S., Poitevin P., Swennen G.N., Vasan S., Egan J.J., Ulrich P., Cerami A., Levy B.I. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:4630-4634.
191. Wu L., Juurlink B.H. Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension 2002, 39:809-814.
192. Xie J., Reverdatto S., Frolov A., Hoffmann R., Burz D.S., Shekhtman A. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J.Biol. Chem. 2008, 283:27255-27269.
193. Xu X., Li Z., Luo D., Huang Y., Zhu J., Wang X., Hu H., Patrick C.P. Exogenous advanced glycosylation end products induce diabetes-like vascular dysfunction in normal rats: a factor in diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2003, 241:56-62.
194. Xue J., Rai V., Singer D., Chabierski S., Xie J., Reverdatto S., Burz D.S., Schmidt A.M., Hoffmann R., Shekhtman A. Advanced glycation end product recognition by the receptor for AGEs. Structure 2011, 19:722-732.
195. Yamagishi S., Yonekura H., Yamamoto Y., Katsuno K., Sato F., Mita I., Ooka H., Satozawa N., Kawakami T., Nomura M., Yamamoto H. Advanced glycation end products-driven angiogenesis invitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J.Biol. Chem. 1997, 272:8723-8730.
196. Yamagishi S., Imaizumi T. Molecular mechanism of diabetic retinopathy: role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic retinopathy. Nihon Ganka Gakkai Zasshi. 2005, 109:338-345.
197. Yamagishi S., Matsui T., Nakamura K., Yoshida T., Takeuchi M., Inoue H., Yoshida Y., Imaizumi T. Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats. Ophthalmic Res. 2007, 39:92-97.
198. Yamagishi S., Ueda S., Okuda S. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr. Pharm. Des. 2007, 13:2832-2836.
199. Yamagishi S., Adachi H., Matsui T., Nakamura K., Takeuchi M., Enomoto M., Fukami A., Otsuka M., Kumagae S., Nanjo Y., Ueda S., Imaizumi T. Low-density lipoprotein levels are one of the independent determinants of circulating levels of advanced glycation end products in nondiabetic subjects. Clin. Cardiol. 2009, 32:E12-E15.
200. Yamagishi S., Matsui T., Adachi H., Takeuchi M. Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population. Pharmacol. Res. 2010, 61:103-107.
201. Yan S.F., Ramasamy R., Schmidt A.M. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ. Res. 2010, 106:842-853.
202. Yao D., Taguchi T., Matsumura T., Pestell R., Edelstein D., Giardino I., Suske G., Ahmed N., Thornalley P.J., Sarthy V.P., Hammes H.P., Brownlee M. Methylglyoxal modification of mSin3A links glycolysis to angiopoietin-2 transcription. Cell 2006, 124:275-286.
203. Yim M.B., Yim H.S., Lee C., Kang S.O., Chock P.B. Protein glycation: creationof catalytic sites for free radical generation. Ann. N. Y. Acad. Sci. 2001, 928:48-53.
204. Yoshida N., Okumura K., Aso Y. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism 2005, 54:345-350.
205. Yoshida Y., Yamagishi S., Matsui T., Jinnouchi Y., Fukami K., Imaizumi T., Yamakawa R. Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy. Diabetes Metab. Res. Rev. 2009, 25:678-686.
206. Yoon K.D., Yamamoto K., Ueda K., Zhou J., Sparrow J.R. Anovel source of methylglyoxal and glyoxal in retina: implications for age-related macular degeneration. PLoS One 2012, 7:e41309.
207. Yuan X., Gu X., Crabb J.S., Yue X., Shadrach K., Hollyfield J.G., Crabb J.W. Quantitative proteomics: comparison of the macular Bruch membrane/choroid complex from age-related macular degeneration and normal eyes. Mol. Cell. Proteomics 2010, 9:1031-1046.
208. Yucel I., Yücel G., Akar Y., Demir N., Gürbüz N., Aslan M. Transmission electron microscopy and autofluorescence findings in the cornea of diabetic rats treated with aminoguanidine. Can. J. Ophthalmol. 2006, 41:60-66.
209. Zarina S., Zhao H.R., Abraham E.C. Advanced glycation end products inhuman senile and diabetic cataractous lenses. Mol. Cell. Biochem. 2000, 210:29-34.
210. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., Simons J.W., Semenza G.L. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000, 60:1541-1545.
211. Zhou W., Yu W., Xie W., Huang L., Xu Y., Li X. The role of SLIT-ROBO signaling in proliferative diabetic retinopathy and retinal pigment epithelial cells. Mol. Vis. 2011, 17:1526-1536.
212. Zhu W., Sano H., Nagai R., Fukuhara K., Miyazaki A., Horiuchi S. The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins. Biochem. Biophys. Res. Commun. 2001, 280:1183-1188.
213. Zicari A.M., Zicari A., Nebbioso M., Mari E., Celani C., Lollobrigida V., Marcelli A.C., Occasi F., Duse M. High-mobility group box-1 (HMGB-1) and serum soluble receptor for advanced glycation end products (sRAGE) in children affected by vernal keratoconjunctivitis. Pediatr. Allergy Immunol. 2014, 25:57-63.
214. Zong H., Ward M., Stitt A.W. AGEs, RAGE, and diabetic retinopathy. Curr. Diab. Rep. 2011, 11:244-252.